RFA-HL-26-011: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2025.
National Institutes of Health offered grants of up to $2,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $2.0 million in total. Applications closed on May 2, 2025.
From the official notice on Grants.gov, last changed January 16, 2025. Checked November 7, 2026.
- Award ceiling$2,000
- Total funding$2.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNHLBI
- Median yearly award$2.8 million
- Typical project length5.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-HL-26-011 were run by National Heart Lung and Blood Institute (NHLBI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-26-011 in the NIH Guide.
Key dates
| Posted | January 16, 2025 |
|---|---|
| Deadline | May 2, 2025 |
| Archived by Grants.gov | June 7, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $2.8 million; it allows up to $2,000 per award.
- Most of the money in the 14 programs behind this notice (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to renew the MACS/WIHS Combined Cohort Study of HIV in United States Adults (MWCCS) for a 6-year project period (2026-2032). Continuation of this epidemiological cohort study of middle-aged and older people living with HIV (PLWH), along with comparable individuals living without HIV (PLWOH) will enable the continued follow-up of a deeply phenotyped cohort of approximately 5,600 participants from across the United States. This initiative will utilize a populomics approach, i.e., examination of health determinants across multiple scales of influence (e.g. molecular, cellular, physiological, lifestyle/behavioral, household, neighborhood, environmental, cultural, and sociopolitical) using multi-disciplinary methods to investigate the web of influences impacting the health, quality of life, and survival of adults living with HIV. This NOFO seeks applications to fund a single Leadership and Coordination Center (LACC) for the MWCCS. This NOFO runs in parallel with two companion U01 NOFOs: RFA-HL-26-009 (Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)) and RFA-HL-26-010 (Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed))
Funded under RFA-HL-26-011 so far
NIH funded 1 project under RFA-HL-26-011 in fiscal 2026, at 1 institution. The median yearly award was $2.8 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| MWCCS Leadership and Coordination Center | University of California, San Francisco | 2026 | $2.8 million |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Other programs behind this notice
- Mental Health Research Grants
- Drug Use and Addiction Research Programs
- Child Health and Human Development Extramural Research
- Cancer Cause and Prevention Research
- Alcohol Research Programs
- Research Related to Deafness and Communication Disorders
- Minority Health and Health Disparities Research
- Oral Diseases and Disorders Research
- Nursing Research
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-26-011 still open?
No. It closed on May 2, 2025.
Who can apply for Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)?
Closed May 2, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2,000 each. About $2.0 million in total.
Who has been funded under RFA-HL-26-011?
NIH RePORTER lists 1 project funded under RFA-HL-26-011 in fiscal 2026, at 1 institution.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)